The Annals of pharmacotherapy
-
To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. ⋯ Sacituzumab govitecan is a novel targeted treatment with promising activity in mTNBC.
-
Data are limited addressing anticoagulant reversal in obese patients using activated prothrombin complex concentrate (aPCC). ⋯ When fixed-dose aPCC is used for warfarin reversal, obesity is associated with a significantly lower rate of INR reversal, without increased bleeding. This study adds to the limited amount of literature on aPCC dosing in obesity.